Open Orphan spin-out Poolbeg upbeat despite losses – 3 March 2022
- The London-listed firm, which counts biochemistry professor Luke O’Neill among its advisory board members, announced a £2.3m (€2.78m) loss in 2021, including a one-off cost from establishing the group last summer.
- Poolbeg is targeting the growing infectious disease market, which is expected to be worth $250bn by 2025, and is due to start human trials for a severe flu treatment in June.
OPEN ORPHAN IDEALLY PLACED TO BENEFIT FROM THE PANDEMIC – 29 July 2021
Open Orphan spin-out Poolbeg Pharma to list on London market – 17 June 2021
Demerger Update on Poolbeg Pharma – 17 June 2021
Open Orphan subsidiary wins €7.5m contract to run study – 26 March 2021
World’s first Covid-19 study where people are infected with virus to begin in London – Government funding of around £33m was given to the human challenge trial. – Shares in Open Ophan, which manages medical trials for a range of pharma companies and universities, are up more than seven per cent on the news. -17 Feb 2021
What happened the Creeslough man who left school early? – 13 Feb 2021
UK taps Open Orphan to explore vaccine trials that infect volunteers with coronavirus – The characterization study is expected to be complete in 2021 and is still subject to ethical and regulatory approval. Sponsored by Imperial College in the U.K., the study will be conducted by Open Orphan’s hVivo unit at a London-based research site. – 20 Oct 2020
Contract Signed with UK Government – 20 Oct 2020
Cathal Friel, Executive Chair, Open Orphan speaking at London South East’s September Webinar – Sickness & Disease the number 1 investment! – 1 Oct 2020